reports
Zelluna ASA [ZLNA]: Annual Report 2024
Zelluna ASA [ZLNA]: Annual Report 2024 Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2024. Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: This information is subject to the disclosure requirements pursuant to Section...
- ABGSC Healthcare Research
- Alexander Krämer
Zelluna ASA [ZLNA]: Ex reverse share split today
Zelluna ASA [ZLNA]: Ex reverse share split today Oslo, Norway, 1 April 2025 Issuer name: Zelluna ASAEx. date: 1 April 2025Type of corporate action: Reverse share split Other information:Reverse split ratio – ten (10) old shares give one (1) new share.New par value of NOK 1 per shareNew ISIN is NO 001 3524942. For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASAEmail: Phone: About Zelluna ASAZelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global sca...
Zelluna ASA [ZLNA]: Registration of reverse share split
Zelluna ASA [ZLNA]: Registration of reverse share split Oslo, Norway, 31 March, 2025 Reference is made to the stock exchange notice published by the Zelluna ASA (the "Company") on 27 March 2025 with key information concerning a reverse share split in the ratio of 10:1. The reverse share split has today been registered with the Norwegian Register of Business Enterprises. After the registration of the reverse share split, the new number of outstanding shares in the Company is 20,227,066, each with a par value of NOK 1. For further information, please contact: Hans Vassgård Eid, CFO, Zellu...
Zelluna ASA [ZLNA]: Key information regarding reverse share split and ...
Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was resolved to carry out a reverse share split in the ratio 10:1. Radforsk Investeringsstiftelse has further agreed with the Company to make available, without any compensation a, necessary number of its existing shares to the Company to ensure that all fractions of shares are rounded up to the nearest whole share...
Zelluna ASA [ZLNA]: Share capital increase registered
Zelluna ASA [ZLNA]: Share capital increase registered Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 26 March 2025 regarding the resolution of the board of directors of Zelluna ASA (the "Company") to carry out a share capital increase of NOK 0.70 through the issuance of seven (7) new shares, each with a par value of NOK 0.10. The share capital increase has today been registered with the Norwegian Register of Business Enterprises. After the share capital increase, the new share capital of the Company is NOK 20,227,066, divided into 202,270,660 sha...
Zelluna ASA [ZLNA]: Notification of transaction by close associate of ...
Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of directors to carry out a share capital increase of NOK 0.70 through the issuance of seven (7) new shares in the Company in order to achieve a desirable ratio for the reverse share split. The Company has received the following notification of a transaction made by a close associate of a primary insider: Radforsk ...
Zelluna ASA [ZLNA]: Share capital increase resolution
Zelluna ASA [ZLNA]: Share capital increase resolution Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was resolved to carry out a reverse share split in the ratio 10:1 and to grant the Company's board of directors a general authorisation to issue shares. As the Company's shares cannot be fully divided by 10, the Company's board of directors has today resolved a share capital increase of NOK 0.70 through the issuance of seven (7) new shares, each w...
- Geir Hiller Holom
Zelluna (No_rec, TP: NOK) - A potential ‘serial killer’
Boosted by encouraging preclinical data and several recent significant deals of relatively early-stage companies in the cell therapy space, we believe Zelluna’s patented TCR-NK platform could be game-changing and unlock extensive potential. While we believe the company needs to show some clinical results to potentially land a deal, it could present early clinical data as early as next year.
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the...
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement Oslo, Norway, 03 March, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, today announces the successful completion of a Business Combination and Private Placement. All conditions for completion of the Business Combination have been met, including, confirmation by Euronext Oslo Børs of the continued listing, approval of the...
Ultimovacs ASA: Approval and publication of prospectus
Ultimovacs ASA: Approval and publication of prospectus NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Oslo, 28 February, 2025: Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement"). ...
Ultimovacs ASA: Cancellation of subsequent repair offering
Ultimovacs ASA: Cancellation of subsequent repair offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Oslo, 13 February, 2025: Reference is made to the stock exchange announcement published by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS, the fully committed private placement (the "Private Placement"), and the intention ...
- ABGSC Healthcare Research
- Alexander Krämer
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provi...
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call and webcast scheduled for January 31, 2025, at 09:00 (CET). Link to webcast . Fourth Quarter 2024 Business Update Highlights On December 17, 2024, Ultimovacs announced an agreement to combine its business with Zelluna Immunotherapy AS and the intention to launch a fully...
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast pres...
Ultimovacs ASA: Invitation to fourth quarter 2024 results webcast presentation Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025. The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Friday, January 31, 2025. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through...
Ultimovacs ASA: Notification of major holdings
Ultimovacs ASA: Notification of major holdings Oslo, 9 January 2025: Reference is made to the stock exchange notices published by Ultimovacs ASA (the "Company") on (i) 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement with gross proceeds of approx. NOK 51.7 million (the "Private Placement") and (ii) today on 9 January 2025 regarding the approval by an extraordinary general meeting of the Company (the "EGM") of relevant resolutions related to the Business Com...
Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025
Ultimovacs ASA – Extraordinary General Meeting held on January 9, 2025 Oslo, January 9, 2025: Ultimovacs ASA held its extraordinary general meeting today January 9, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s website. For further information, please see or contact: Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA Email: Phone: Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA Email: Phone: Attachment
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General ...
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting Oslo, January 8, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,652,094 shares, representing 25.15% of the total voting rights in the company. The proxies are only valid for the Extraordinary General Meeting on January 9, 2025. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norweg...
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General ...
Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting Oslo, January 6, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,020,964 shares, representing 23.31% of the total voting rights in the company. The proxies are only valid for the Extraordinary General Meeting on January 9, 2025. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norweg...
Ultimovacs ASA: Regarding the extraordinary general meeting on 9 Janua...
Ultimovacs ASA: Regarding the extraordinary general meeting on 9 January 2025 Oslo, 5 January 2025: Reference is made to the stock exchange notice published by Ultimovacs ASA on 19 December 2024 regarding the call for an extraordinary general meeting to be held on 9 January 2025 at 09:00 CET (the "EGM"). As described in the previously published EGM notice, one additional proposal for a board member would be announced prior to the EGM. The complete proposal for the board of directors is now complete and attached hereto. For further information, please see or contact: Hans Vassgård E...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.